Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
Delayed Quote. Delayed Nasdaq - 08/16 04:00:00 pm
204.02 USD   +2.36%
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
205.78(c) 206.12(c) 198.87(c) 199.31(c) 204.02(c) Last
10 599 278 5 647 558 4 533 821 3 105 128 2 909 796 Volume
+4.86% +0.17% -3.52% +0.22% +2.36% Change
More quotes
Financials (USD)
Sales 2019 22 830 M
EBIT 2019 10 915 M
Net income 2019 7 711 M
Debt 2019 2 336 M
Yield 2019 2,84%
Sales 2020 23 051 M
EBIT 2020 11 089 M
Net income 2020 8 088 M
Finance 2020 1 119 M
Yield 2020 3,00%
P/E ratio 2019 16,1x
P/E ratio 2020 15,1x
EV / Sales2019 5,46x
EV / Sales2020 5,26x
Capitalization 122 B
More Financials
Company
Amgen is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.9%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 77.3% of net sales; - other (5.1%):... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
08/12Health Care Down, But Losses Limited by Lack of Cyclical Exposure -- Health C..
DJ
08/12Amgen and Sysco rise while Viacom and Bank of America fall
AQ
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
08/09Wall Street ends down amid more trade woes, high volatility
RE
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09AMGEN : Wins Patent Case On Enbrel® (etanercept)
PR
More news
Analyst Recommendations on AMGEN
More recommendations
Stock Trading Strategies
AMGEN - 2018
Comeback of a rising trend ?
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
08/16ABBVIE : Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
DJ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/16NOVO NORDISK : contests Danish lawsuit claiming $1.75 billion
RE
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
More sector news : Pharmaceuticals - NEC
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 209,76  $
Last Close Price 204,02  $
Spread / Highest target 13,2%
Spread / Average Target 2,81%
Spread / Lowest Target -15,2%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN2.38%119 526
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958